Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Monday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.0 %

NYSE:BTX opened at $0.21 on Monday. The company has a market cap of $12.07 million, a price-to-earnings ratio of -0.09 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The stock has a fifty day simple moving average of $0.79 and a 200-day simple moving average of $1.39.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.